IngentaConnect The Search for gamma-Secretase and Development of Inhibitors

Authors: Tsai J-Y.; Wolfe M.S.; Xia W.

Source: Current Medicinal Chemistry, Volume 9, Number 11, June 2002 , pp. 1087-1106(20)

Publisher: Bentham Science Publishers

Abstract:

A considerable body of evidence has accumulated in recent years implicating the ß-amyloid protein (Aß) in the etiology of Alzheimer's disease (AD). The highly hydrophobic Aß can nucleate and form neurotoxic fibrils that are the principal components of the cerebral plaques characteristic of AD. Aß is formed from the amyloid-ßprecursor protein (APP) through two protease activities. First, ß-secretase cleaves APP at the Aß N-terminus, resulting in a soluble, secreted APP derivative (ß-APPs) and a 12 kDa membrane-retained C-terminal fragment. The latter is further processed to Aß by ggr secretases, which cleave within the single transmembrane region. Other APP molecules can be cleaved by agr -secretase within the Aß region, thus precluding Aß formation. Both bgr - and ggr - secretase have become prime targets for the development of therapeutic agent that reduce A bgr production. bgr -Secretase has recently been identified as a new membrane-anchored aspartyl protease in the cathepsin D family. Inhibitor profiling, site-directed mutagenesis, and affinity labeling together have suggested that the multi-pass presenilins are ggr -secretases, novel intramembrane-cleaving aspartyl proteases activated through autoproteolysis. In this article, we review the current knowledge of ggr -secretase biochemistry and cell biology and the development of inhibitors of this important therapeutic target.

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$55.10 plus tax Refund Policy

The Search for -Secretase and Development of Inhibitors